

# PRODUCT INFORMATION




## KDU691

Item No. 29019

**CAS Registry No.:** 1513879-19-0  
**Formal Name:** N-(4-chlorophenyl)-N-methyl-3-[4-  
[(methylamino)carbonyl]phenyl]-  
imidazo[1,2-a]pyrazine-6-carboxamide

**MF:** C<sub>22</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>2</sub>  
**FW:** 419.9  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 223, 268 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

KDU691 is supplied as a crystalline solid. A stock solution may be made by dissolving the KDU691 in the solvent of choice, which should be purged with an inert gas. KDU691 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of KDU691 in these solvents is approximately 30 mg/ml.

KDU691 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KDU691 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. KDU691 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

KDU691 is an antimalarial compound.<sup>1</sup> It inhibits recombinant *P. vivax* phosphatidylinositol 4-kinase (PI4K) with an IC<sub>50</sub> value of 1.5 nM. KDU691 is selective for *P. vivax* PI4K over recombinant human PI4KβIII and PI3Kα, -β, -γ, and -δ (IC<sub>50</sub>s = 7.9, 8.8, 2.4, 8, and 3.4 μM, respectively), as well as VPS34 (IC<sub>50</sub> = >9.7 μM) and 36 additional kinases in a panel of lipid and protein kinases (IC<sub>50</sub>s = >10 μM). It is active against *P. falciparum* and *P. yoelii* schizonts (IC<sub>50</sub>s = 0.06 and 0.04 μM, respectively), as well as *P. cynomolgi* schizonts and hypnozoites (IC<sub>50</sub>s = 0.11 and 0.2 μM, respectively).<sup>2</sup> KDU691 completely prevents, but does not eradicate established, *P. cynomolgi* infection in rhesus monkeys when administered at a dose of 20 mg/kg.<sup>3</sup>

### References

- McNamara, C.W., Lee, M.C., Lim, C.S., *et al.* Targeting *Plasmodium* phosphatidylinositol 4-kinase to eliminate malaria. *Nature* **504(7479)**, 248-253 (2013).
- Zou, B., Nagle, A., Chatterjee, A.K., *et al.* Lead optimization of imidazopyrazines: a new class of antimalarial with activity on *Plasmodium* liver stages. *ACS Med. Chem. Lett.* **5(8)**, 947-950 (2014).
- Zeeman, A.M., Lakshminarayana, S.B., van der Werff, N., *et al.* PI4 kinase is a prophylactic but not radical curative target in *Plasmodium vivax*-type malaria parasites. *Antimicrob. Agents Chemother.* **60(5)**, 2858-2863 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM